CIBMTR is a research collaboration between the NMDP/Be The Match and Medical College of Wisconsin.
|
New eLearning this month
"Infusion Data (Form 2006) Reporting Overview"
This module was authored by Alisha Mussetter, Katie Newcomb, and Jenni Bloomquist. It provides a high level overview of the Form 2006 including appropriate completion of the form. It is approximately 25 minutes in length. Following completion of the eLearning is an exam to be taken with the Form 2006 Instruction Manual open. You will find this eLearning in our Learning Center, under the category CIBMTR Data Management. Subsequent modules in development will further explain product analysis and product identifiers.
|
Question: Reporting on the Pre-TED (Form 2400) - Myelofibrosis
A patient was diagnosed with Essential Thrombocytosis (ET) in the year 2000 and received treatment with Anagrelide. In 2014, the patient developed pancytopenia. A BMBx was obtained & it documented myelofibrosis. How should this be reported on the Pre-TED (Form 2400)?
Answer:
Some patients with Essential Thrombocytosis (ET) may develop marrow fibrosis (myelofibrosis) as a later stage of the disease. This type of myelofibrosis would be considered secondary and should not be reported as primary myelofibrosis. The correct diagnosis to report at transplant is ET. One should not report the development of myelofibrosis as a transformation. In other words, Question #525 on the Pre-TED (Form 2400) should be answered "no".
|